Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres.

Site-specific delivery of angiogenic growth factors from tissue-engineered devices should provide an efficient means of stimulating localized vessel recruitment to the cell transplants and would ensure cell survival and function. In the present article, we describe the construction of a novel porous alginate scaffold that incorporates tiny poly (lactic-co-glycolic acid) microspheres capable of controlling the release of angiogenic factors, such as basic fibroblast growth factor (bFGF). The microspheres are an integral part of the solid alginate matrix, and their incorporation does not affect the scaffold porosity or pore size. In vitro, bFGF was released from the porous composite scaffolds in a controlled manner and it was biologically active as assessed by its ability to induce the proliferation of cardiac fibroblasts. The controlled delivery of bFGF from the three-dimensional scaffolds accelerated the matrix vascularization after implantation on the mesenteric membrane in rat peritoneum. The number of penetrating capillaries into the bFGF-releasing scaffolds was nearly fourfold higher than into the control scaffolds (those incorporating microspheric BSA and heparin but not bFGF). At day 10 posttransplantation, capillary density in the composite scaffolds was 45 +/- 3/mm(2) and it increased to 70 +/- 7/mm(2) by day 21. The released bFGF induced the formation of large and matured blood vessels, as judged by the massive layer of mural cells surrounding the endothelial cells. The control over bFGF delivery and localizing its effects to areas of need, may aid in the wider application of bFGF in therapeutic angiogenesis as well as in tissue engineering.

[1]  D. Gospodarowicz,et al.  Brain-derived fibroblast growth factor: a study of its inactivation. , 1983, Life Science.

[2]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[3]  D. Gospodarowicz,et al.  Structural characterization and biological functions of fibroblast growth factor. , 1987, Endocrine reviews.

[4]  D. Gospodarowicz,et al.  Identification of the fibroblast growth factor receptor in human vascular endothelial cells , 1988, Journal of cellular physiology.

[5]  T. Maciag,et al.  The heparin-binding (fibroblast) growth factor family of proteins. , 1989, Annual review of biochemistry.

[6]  Fibroblast growth factors. , 1989, British medical bulletin.

[7]  J. Folkman,et al.  The fate of intravenously administered bFGF and the effect of heparin. , 1989, Growth factors.

[8]  B. Matthews,et al.  Three-dimensional structure of human basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R Langer,et al.  Controlled and modulated release of basic fibroblast growth factor. , 1991, Biomaterials.

[10]  J. Vacanti,et al.  Tissue engineering : Frontiers in biotechnology , 1993 .

[11]  J. Vacanti,et al.  Injectable alginate seeded with chondrocytes as a potential treatment for vesicoureteral reflux. , 1993, The Journal of urology.

[12]  E. Edelman,et al.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Dell’Era,et al.  Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. , 1994, Biochemical and biophysical research communications.

[14]  T. Arakawa,et al.  Stoichiometry of heparin binding to basic fibroblast growth factor. , 1994, Archives of biochemistry and biophysics.

[15]  Y. Baruch,et al.  Basic fibroblast growth factor is hepatotropic for rat liver in regeneration. , 1995, Journal of hepatology.

[16]  C. Colton,et al.  Implantable biohybrid artificial organs. , 1995, Cell transplantation.

[17]  Clark K. Colton,et al.  Implantable Biohybrid Artificial Organs , 1995 .

[18]  E. Edelman,et al.  Cellular Response to Transforming Growth Factor-β1 and Basic Fibroblast Growth Factor Depends on Release Kinetics and Extracellular Matrix Interactions* , 1996, The Journal of Biological Chemistry.

[19]  L. Shapiro,et al.  Novel alginate sponges for cell culture and transplantation. , 1997, Biomaterials.

[20]  Smadar Cohen,et al.  Characterization of PLGA microspheres for the controlled delivery of IL-1α for tumor immunotherapy , 1997 .

[21]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[22]  Y. Ikada,et al.  Vascularization into a porous sponge by sustained release of basic fibroblast growth factor. , 1999, Journal of biomaterials science. Polymer edition.

[23]  Robert Langer,et al.  Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation , 1999, The Lancet.

[24]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[25]  D. Ecker,et al.  Transplantation of islets using microencapsulation: studies in diabetic rodents and dogs , 1999, Journal of Molecular Medicine.

[26]  J. Merchuk,et al.  Hepatocyte behavior within three-dimensional porous alginate scaffolds. , 2000, Biotechnology and bioengineering.

[27]  E. Voronov,et al.  Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres. , 2000, Cytokine.

[28]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[29]  M. Tanihara,et al.  Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate. , 2001, Journal of biomedical materials research.

[30]  A A Poot,et al.  Binding and release of basic fibroblast growth factor from heparinized collagen matrices. , 2001, Biomaterials.

[31]  K. Sugimachi,et al.  Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 but not of Fibroblast Growth Factor-2 , 2002, Circulation research.

[32]  Smadar Cohen,et al.  Optimization of cardiac cell seeding and distribution in 3D porous alginate scaffolds. , 2002, Biotechnology and bioengineering.

[33]  Smadar Cohen,et al.  Tailoring the pore architecture in 3-D alginate scaffolds by controlling the freezing regime during fabrication. , 2002, Biomaterials.

[34]  Robert Langer,et al.  Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres , 1991, Pharmaceutical Research.